Naloxone Deployment Fund Initiative
The mission of this initiative is to provide funding to Oregon-Idaho HIDTA participating agencies for the purchase of naloxone for police officer use in the communities that they serve in order to reduce the number of opioid overdose deaths.
With increasing frequency and in an increasing large geographic area, public safety agencies are responding to opioid drug overdose incidents where the victim is, or soon will be unresponsive and whose chances of survival are greatly increased when the overdose is interrupted by the application of naloxone; an opioid antagonist drug that will reverse an opioid overdose. Public safety agency naloxone programs within Oregon and throughout the United States have been proven to reduce the number of opioid overdose deaths. This support initiative will provide funding to Oregon-Idaho HIDA initiative participating agencies to purchase naloxone for law enforcement deployment within communities in order to reduce the number of opioid overdose deaths.
To access these funds, download, complete and send the application Chris Gibson at firstname.lastname@example.org. The Oregon‐Idaho HIDTA program Executive Board Finance Subcommittee will review all funding requests and determine the appropriate amount to be granted. Funds awarded will be on a one time, reimbursement basis. These funds may only be used for the purchase of naloxone kits. Project outcomes will be provided, upon request, to the Project Manager of the Oregon‐Idaho HIDTA program.
Applying law enforcement agencies shall establish and include with this application, a policy for naloxone use and resupply.
This policy shall be consistent with applicable state laws and outline how naloxone will be used. The policy should include: 1) the primary locations of the naloxone kits (e.g., Desk Sergeant / Booking area, one in each patrol car & K‐9 Units, Drug Control Unit, Law Enforcement Department Commander Office, etc.), 2) a maintenance and plan (e.g., process for inspection of kits), 3) resupply plan (e.g., reorder process), 4) an officer universal precaution directive; 5) pre and post naloxone application victim/patient assessment guidelines, 6) a medical transportation plan, and 7) a naloxone use reporting plan.
Applying law enforcement agencies shall establish and include with this application an agency naloxone training and reporting plan. The training plan should cover and provide for documentation of appropriate training on the signs of overdose, the proper administration of naloxone to overdose victims/patients and post naloxone aftercare to overdose victims/patients.
The reporting plan shall establish a system to document each naloxone administration and the results of each administration. The reporting system should document: 1) the documentation of the date, time and location of the naloxone administration, 2) the gender, age and race of the overdose victim/patient, 3) the drug that caused the overdose, if known, 4) the number of doses used on the overdose victim/patient and 5) whether or not the overdose victim/patient survived. The reporting plan should include a data sharing provision that allows for the information to be shared with the Oregon-Idaho HIDTA for the purpose of program analysis. (A sample report form may be adopted and used by applying law enforcement agencies is included with the application.)
Applying law enforcement agencies shall establish and include with this application an agency Medical Authorization Plan to purchase naloxone.
Naloxone is a prescription medication and authorization is required to allow possession and administration of the drug by first responders. To obtain naloxone, the law enforcement agency will need to collaborate with physicians from the state or local departments of health, hospitals, or community organizations and sign an agreement to formalize this collaboration. In the case of large departments, the agency’s medical director or other licensed staff prescribers may provide medical oversight for the naloxone program.
To receive information about ordering naloxone, please contact Chris Gibson at email@example.com.